Association between paraoxonase gene and stroke in the Han Chinese population

BMC Medical Genetics

Volumn 14, Issue 1, 2013, Pages

  Zhang, Guojun ^a   Li, Wenjin ^b   Li, Zhiqiang ^b   Lv, Hong ^a   Ren, Yonghong ^c,d   Ma, Ruimin ^a   Li, Xiaohong ^c,d   Kang, Xixiong ^a   Shi, Yongyong ^b   Sun, Yimin ^c,d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c CapitalBio Corporation   (China)

^d NATIONAL ENGINEERING RESEARCH CENTER FOR BEIJING BIOCHIP TECHNOLOGY   (China)

Author keywords

Association; Hemorrhagic stroke; Ischemic stroke; Paraoxanase gene; Polymorphisms

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; ARYLDIALKYLPHOSPHATASE 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ARYLDIALKYLPHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CEREBRAL HEMORRHAGE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; STROKE;

EID: 84872802463     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-14-16     Document Type: Article

References (47)

1. Adams H, Bendixen B, Kappelle L, Biller J, Love B, Gordon D, Marsh E. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24(1):35-41.
2. Liao DP, Myers R, Hunt S, Shahar E, Paton C, Burke G, Province M, Heiss G. Familial history of stroke and stroke risk - The family heart study. Stroke 1997, 28(10):1908-1912.
3. de Lange M, Snieder H, Ariens RAS, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet 2001, 357(9250):101-105.
4. Bak S, Gaist D, Sindrup SH, Skytthe A, Christensen K. Genetic liability in stroke - a long-term follow-up study of Danish twins. Stroke 2002, 33(3):769-774.
5. Rubattu S, Volpe M, Kreutz R, Ganten U, Ganten D, Lindpaintner K. Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease. Nat Genet 1996, 13(4):429-434.
6. Jeffs B, Clark JS, Anderson NH, Gratton J, Brosnan MJ, Gauguier D, Reid JL, Macrae IM, Dominiczak AF. Sensitivity to cerebral ischaemic insult in a rat model of stroke is determined by a single genetic locus. Nat Genet 1997, 16(4):364-367.
7. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch S, Domenga V, Cecillion M, Marechal E, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996, 383(6602):707-710.
8. Petersen NH, Schmied AB, Zeller JA, Plendl H, Deuschl G, Zunker P. Lp(a) lipoprotein and plasminogen activity in patients with different etiology of ischemic stroke. Cerebrovasc Dis 2007, 23(2-3):188-193.
9. Lernfelt B, Forsberg M, Blomstrand C, Mellstrom D, Volkmann R. Cerebral atherosclerosis as predictor of stroke and mortality in representative elderly population. Stroke 2002, 33(1):224-229.
10. Nagai Y, Kitagawa K, Sakaguchi M, Shimizu Y, Hashimoto H, Yamagami H, Narita M, Ohtsuki T, Hori M, Matsumoto M. Significance of earlier carotid atherosclerosis for stroke subtypes. Stroke 2001, 32(8):1780-1785.
11. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Eng J Med 1989, 321(19):1311-1316.
12. Kozarsky KF, Donahee MH, Glick JM, Krieger M, Rader DJ. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 2000, 20(3):721-727.
13. Primo-Parmo SL, Sorenson RC, Teiber J, Du BNL. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33(3):498-507.
14. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001, 21(4):542-547.
15. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991, 286(1-2):152-154.
16. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - a possible peroxidative role for paraoxonase. J Clin Invest 1998, 101(8):1581-1590.
17. Tward A, Xia Y-R, Wang X-P, Shi Y-S, Park C, Castellani LW, Lusis AJ, Shih DM. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106(4):484-490.
18. Mackness MI, Arrol S, Abbott CA, Durrington PN. Is paraoxonase related to atherosclerosis. Chem Biol Interact 1993, 87(1-3):161-171.
19. Kim NS, Kang K, Cha MH, Kang BJ, Moon J, Kang BK, Yu BC, Kim YS, Choi SM, Bang OS. Decreased paraoxonase-1 activity is a risk factor for ischemic stroke in Koreans. Biochem Biophys Res Commun 2007, 364(1):157-162.
20. Michalak S, Kazmierski R, Hellmann A, Wysocka E, Kocialkowska-Adamczewska D, Wencel-Warot A, Nowinski WL. Serum paraoxonase/arylesterase activity affects outcome in ischemic stroke patients. Cerebrovasc Dis 2011, 32(2):124-132.
21. Martinelli N, Micaglio R, Consoli L, Guarini P, Grison E, Pizzolo F, Friso S, Trabetti E, Pignatti PF, Corrocher R, et al. Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease. Exp Diabetes Res 2012, 2012:231502.
22. Slowik A, Wloch D, Szermer P, Wolkow P, Malecki M, Pera J, Turaj W, Dziedzic T, Klimkowicz-Mrowiec A, Kopec G, et al. Paraoxonase 2 gene C311S polymorphism is associated with a risk of large vessel disease stroke in a Polish population. Cerebrovasc Dis 2007, 23(5-6):395-400.
23. Voetsch B, Benke KS, Panhuysen CI, Damasceno BP, Loscalzo J. The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. Arch Neurol 2004, 61(3):351-356.
24. Ranade K, Kirchgessner TG, Iakoubova OA, Devlin JJ, DelMonte T, Vishnupad P, Hui L, Tsuchihashi Z, Sacks FM, Sabatine MS, et al. Evaluation of the paraoxonases as candidate genes for stroke - Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke 2005, 36(11):2346-2350.
25. Voetsch B, Benke KS, Damasceno BP, Siqueira LH, Loscalzo J. Paraoxonase 192 Gln Arg polymorphism - an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 2002, 33(6):1459-1464.
26. Xiao ZJ, Chen J, Sun Y, Zheng ZJ. Lack of association between the Paraoxonase 1 Q/R192 single nucleotide polymorphism and stroke in a Chinese cohort. Acta Neurol Belg 2009, 109(3):205-209.
27. Pasdar A, Ross-Adams H, Cumming A, Cheung J, Whalley L, St Clair D, MacLeod MJ. Paraoxonase gene polymorphisms and haplotype analysis in a stroke population. BMC Med Genet 2006, 7:28.
28. Huang Q, Liu Y-H, Yang Q-D, Xiao B, Ge L, Zhang N, Xia J, Zhang L, Liu Z-J. Human serum paraoxonase gene polymorphisms, Q192R and L55M, are not associated with the risk of cerebral infarction in Chinese Han population. Neurolog Res 2006, 28(5):549-554.
29. Xu HW, Yuan N, Zhao Z, Zhang L, Xia J, Zeng KM, Xiao B, Yang XS, Tang BS. Study of the relationship between gene polymorphisms of paraoxonase 2 and stroke in a chinese population. Cerebrovasc Dis 2008, 25(1-2):87-94.
30. Xu XW, Li JJ, Sheng WL, Liu L. Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovasc Dis 2008, 26(1):48-62.
31. Afridi I, Canny J, Yao CH, Christensen B, Cooper RS, Kadiri S, Hill S, Kaplan N, Kuschnir E, Lexchin J, et al. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003, 21(11):1983-1992.
32. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. The Am J Human Genetics 2007, 81(3):559-575.
33. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
34. Burkett K, Graham J, McNeney B. Hapassoc: software for likelihood inference of trait associations with SNP haplotypes and other attributes. J Stat Softw 2006, 16(2):1-19.
35. Dahabreh IJ, Kitsios GD, Kent DM, Trikalinos TA. Paraoxonase 1 polymorphisms and ischemic stroke risk: a systematic review and meta-analysis. Genet Med 2010, 12(10):606-615.
36. Leviev N, Righetti A, James RW. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med 2001, 79(8):457-463.
37. Deakin S, Leviev I, Brulhart-Meynet MC, James RW. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position-107, implicating the Sp1 transcription factor. Biochem Jl 2003, 372:643-649.
38. Demirdogen BC, Demirkaya S, Turkanoglu A, Bek S, Arinc E, Adali O. Analysis of paraoxonase 1 (PON1) genetic polymorphisms and activities as risk factors for ischemic stroke in Turkish population. Cell Biochem Funct 2009, 27(8):558-567.
39. Karakaya A, Ibis S, Kural T, Kose SK, Karakaya AE. Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins. Chemico-Biol Interact 1999, 118(3):193-200.
40. Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001, 11(1):77-84.
41. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5 ' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genetics 2001, 68(6):1428-1436.
42. Hofer SE, Bennetts B, Chan AK, Holloway B, Karschimkus C, Jenkins AJ, Silink M, Donaghue KC. Association between PON 1 polymorphisms, PON activity and diabetes complications. Jf Diabetes Complicats 2006, 20(5):322-328.
43. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000, 20(2):516-521.
44. Freedman ML, Reich D, Penney KL, McDonald GJ, Mignault AA, Patterson N, Gabriel SB, Topol EJ, et al. Assessing the impact of population stratification on genetic association studies. Nat Genet 2004, 36(4):388-493.
45. Du R. Genetics of Chinese population. Beijing Sci Publish 2004, 10:414-419.
46. Wang X, Fan Z, Huang J, Su S, Yu Q, Zhao J, Hui R, Yao Z, Shen Y, Qiang B, et al. Extensive association analysis between oolymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscle Tthromb Vasc Biol 2003, 23(2):328-334.
47. Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection?. Lancet Oncol 2009, 10(8):825-833.